NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
Clinical Trials
7 trialsNCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT05422911 2022-06-21
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
James J. Peters Veterans Affairs Medical Center
Phase 2 Not yet recruiting
NCT01842321 2021-02-23
AMA
UNICANCER
Phase 2 Completed
NCT01940276 2020-12-09
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
Duke University
Phase 2 Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed